ABSTRACT
PURPOSE: In VELIA trial, veliparib combined with carboplatin-paclitaxel, followed by maintenance (veliparib-throughout) was associated with improved progression-free survival (PFS) compared with carboplatin-paclitaxel alone in patients with high-grade ovarian carcinomas. We explored the prognostic value of the modeled cancer antigen (CA)-125 elimination rate constant K (KELIM), which is known to be an indicator of the intrinsic tumor chemosensitivity (the faster the rate of CA-125 decline, the higher the KELIM and the higher the chemosensitivity), and its association with benefit from veliparib. PATIENTS AND METHODS: Individual KELIM values were estimated from longitudinal CA-125 kinetics. Patients were categorized as having favorable (≥ median) or unfavorable (< median) KELIM. The prognostic value of KELIM for veliparib-related PFS benefit was explored in cohorts treated with primary or interval debulking surgery, according to the surgery completeness, the disease progression risk group, and the homologous recombination (HR) status (BRCA mutation, HR deficiency [HRD], or HR proficiency [HRP]). RESULTS: The data from 854 of 1,140 enrolled patients were analyzed (primary debulking surgery, n = 700; interval debulking surgery, n = 154). Increasing KELIM values were associated with higher benefit from veliparib in HRD cancer, as were decreasing KELIM values in HRP cancer. The highest PFS benefit from veliparib was observed in patients with both favorable KELIM and BRCA mutation (hazard ratio, 0.28; 95% CI, 0.13 to 0.61) or BRCA wild-type HRD cancer (hazard ratio, 0.43; 95% CI, 0.26 to 0.70), consistent with the association between poly (adenosine diphosphate-ribose) polymerase inhibitor efficacy and platinum sensitivity. In contrast, seventy-four percent of patients with a BRCA mutation and unfavorable KELIM progressed within 18 months while on veliparib. The patients with HRP cancer and unfavorable KELIM might have benefited from the veliparib chemosensitizing effect. CONCLUSION: In addition to HRD/BRCA status, the tumor primary chemosensitivity observed during the first-line chemotherapy might be another complementary determinant of poly (adenosine diphosphate-ribose) polymerase inhibitor efficacy.
Subject(s)
Ovarian Neoplasms , Ribose , Female , Humans , Carboplatin/therapeutic use , Ribose/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , Paclitaxel , Adenosine Diphosphate/therapeutic useABSTRACT
BACKGROUND: Seaweed polysaccharides have been recommended as anticancer supplements and for boosting human health; however, their benefits in the treatment of triple-negative breast cancers (TNBCs) and improving immune surveillance remain unclear. Olaparib is a first-in-class poly (ADP-ribose) polymerase inhibitor. Oligo-Fucoidan, a low-molecular-weight sulfated polysaccharide purified from brown seaweed (Laminaria japonica), exhibits significant bioactivities that may aid in disease management. METHODS: Macrophage polarity, clonogenic assays, cancer stemness properties, cancer cell trajectory, glucose metabolism, the TNBC 4T1 cells and a 4T1 syngeneic mouse model were used to inspect the therapeutic effects of olaparib and Oligo-Fucoidan supplementation on TNBC aggressiveness and microenvironment. RESULTS: Olaparib treatment increased sub-G1 cell death and G2/M arrest in TNBC cells, and these effects were enhanced when Oligo-Fucoidan was added to treat the TNBC cells. The levels of Rad51 and programmed death-ligand 1 (PD-L1) and the activation of epidermal growth factor receptor (EGFR) and adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) facilitate drug resistance and TNBC metastasis. However, the combination of olaparib and Oligo-Fucoidan synergistically reduced Rad51 and PD-L1 levels, as well as the activity of EGFR and AMPK; consistently, TNBC cytotoxicity and stemness were inhibited. Oligo-Fucoidan plus olaparib better inhibited the formation of TNBC stem cell mammospheroids with decreased subpopulations of CD44high/CD24low and EpCAMhigh cells than monotherapy. Importantly, Oligo-Fucoidan plus olaparib repressed the oncogenic interleukin-6 (IL-6)/p-EGFR/PD-L1 pathway, glucose uptake and lactate production. Oligo-Fucoidan induced immunoactive and antitumoral M1 macrophages and attenuated the side effects of olaparib, such as the promotion on immunosuppressive and protumoral M2 macrophages. Furthermore, olaparib plus Oligo-Fucoidan dramatically suppressed M2 macrophage invasiveness and repolarized M2 to the M0-like (F4/80high) and M1-like (CD80high and CD86high) phenotypes. In addition, olaparib- and Oligo-Fucoidan-pretreated TNBC cells resulted in the polarization of M0 macrophages into CD80(+) M1 but not CD163(+) M2 macrophages. Importantly, olaparib supplemented with oral administration of Oligo-Fucoidan in mice inhibited postsurgical TNBC recurrence and metastasis with increased cytotoxic T cells in the lymphatic system and decreased regulatory T cells and M2 macrophages in tumors. CONCLUSION: Olaparib supplemented with natural compound Oligo-Fucoidan is a novel therapeutic strategy for reprogramming cancer stemness, metabolism and the microenvironment to prevent local postsurgical recurrence and distant metastasis. The combination therapy may advance therapeutic efficacy that prevent metastasis, chemoresistance and mortality in TNBC patients.
Subject(s)
Antineoplastic Agents , Triple Negative Breast Neoplasms , AMP-Activated Protein Kinases , Adenosine/pharmacology , Adenosine Diphosphate/pharmacology , Adenosine Diphosphate/therapeutic use , Adenosine Monophosphate/pharmacology , Adenosine Monophosphate/therapeutic use , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Apoptosis , B7-H1 Antigen , Cell Line, Tumor , Dietary Supplements , Epithelial Cell Adhesion Molecule , ErbB Receptors , G2 Phase Cell Cycle Checkpoints , Glucose , Humans , Interleukin-6 , Lactates/pharmacology , Lactates/therapeutic use , Mice , Phthalazines , Piperazines , Poly(ADP-ribose) Polymerase Inhibitors/pharmacology , Polysaccharides/therapeutic use , Ribose/pharmacology , Ribose/therapeutic use , Triple Negative Breast Neoplasms/drug therapy , Triple Negative Breast Neoplasms/metabolism , Triple Negative Breast Neoplasms/pathologyABSTRACT
Fibrinogen γ-chain peptide-coated, adenosine 5'-diphosphate (ADP)-encapsulated liposomes (H12-ADP-liposomes) are a potent haemostatic adjuvant to promote platelet thrombi. These liposomes are lipid particles coated with specific binding sites for platelet GPIIb/IIIa and encapsulating ADP. They work at bleeding sites, facilitating haemostasis by promoting aggregation of activated platelets and releasing ADP to strongly activate platelets. In this study, we investigated the therapeutic potential of H12-ADP-liposomes on post-cardiopulmonary bypass (CPB) coagulopathy in a preclinical setting. We created a post-CPB coagulopathy model using male New Zealand White rabbits (body weight, 3 kg). One hour after CPB, subject rabbits were intravenously administered H12-ADP-liposomes with platelet-rich plasma (PRP) collected from donor rabbits (H12-ADP-liposome/PRP group, n = 8) or PRP alone (PRP group, n = 8). Ear bleeding time was greatly reduced for the H12-ADP-liposome/PRP group (263 ± 111 s) compared with the PRP group (441 ± 108 s, p < 0.001). Electron microscopy showed platelet thrombus containing liposomes at the bleeding site in the H12-ADP-liposome/PRP group. However, such liposome-involved platelet thrombi were not observed in the end organs after H12-ADP-liposome administration. These findings suggest that H12-ADP-liposomes could help effectively and safely consolidate platelet haemostasis in post-CPB coagulopathy and may have potential for reducing bleeding complications after cardiovascular surgery with CPB.
Subject(s)
Adenosine Diphosphate/therapeutic use , Adjuvants, Pharmaceutic/therapeutic use , Blood Coagulation Disorders/drug therapy , Fibrinogen/therapeutic use , Liposomes/therapeutic use , Animals , Blood Coagulation/drug effects , Cardiopulmonary Bypass/adverse effects , Hemostatics/therapeutic use , Platelet Aggregation/drug effects , RabbitsABSTRACT
Treatment of venous and lymphatic insufficiency of the lower limbs is based on 3 components: elastic support, venotonic drugs and radical treatments (surgery or sclerotherapy) of insufficient veins. Venotonic drugs have specific indications limited to functional impairment: heavy feeling in the legs, pain and impatience in the evening. There are different categories of venolymphatic drugs. Flavonoids have various pharmacological actions, most notably an increase in venous tone, reduction of capillary permeability and increase of capillary resistance. Choice of a venotonic drug is funded on knowledge of pharmacodynamics and pharmacokinetics of the molecule, critical evaluation of clinical studies, physician's personal experience and drug cost. Venotonic drugs are useful when venous insufficiency leads to functional manifestations. They are especially the treatment of heavy leg syndromes during warm seasons when elastic support is uncomfortable.
Subject(s)
Vasodilator Agents/therapeutic use , Venous Insufficiency/drug therapy , Adenosine Diphosphate/therapeutic use , Ascorbic Acid/therapeutic use , Capillary Permeability/drug effects , Capillary Resistance/drug effects , Drug Costs , Flavonoids/therapeutic use , Ginkgo biloba/therapeutic use , Humans , Patient Selection , Phytotherapy , Plants, Medicinal , Vasodilator Agents/classification , Vasodilator Agents/economics , Vasodilator Agents/pharmacology , Venous Insufficiency/etiology , Venous Insufficiency/physiopathologyABSTRACT
Clopidogrel es un nuevo antiagregante plaquetario, análogo de la ticoplidina, que actúa mediante la unión selectiva al receptor adenosíndifosfato plaquetar acoplado a adenilato ciclasa bloqueando la cascada de la agregación. Administrado por vía oral se trasforma en el hígado, en su metabolito activo. Su eficacia se ha puesto de manifiesto en un gran estudio (CAPRIE), donde se compara con ácido acetilsalicílico evidenciando su utilidad en la reducción del riesgo combinado de accidente cerebro vascular isquémico, infarto de miocardio o muerte vascular, con un perfil de seguridad muy adecuado (AU)
Clopidogrel is a new platelet inhibitor drugitidopidine analogue, which acts by selective attaching to the ADP receptors mediating the inhibition of stimulated adenylcyclase activity by ADP. Administred by oral route, hepatic metabolization is necessary for the appearance of its antiaggregatory activity. lts efficacy has been demostrated in the double-blind efficacy and safety CAPRlEstudy (Clopidogrel versus acetyl salicilate), appearing to be a promising compound for evaluation in atherosclerotic, cardiovascular, cerebrovascular and peripheral arterial diseases with an adequate safety profile (AU)
Subject(s)
Humans , Male , Female , Platelet Aggregation Inhibitors/metabolism , Platelet Aggregation Inhibitors/therapeutic use , Adenosine Diphosphate/therapeutic use , Drug Interactions/physiology , Homeopathic Dosage/standards , Ticlopidine/chemistry , Ticlopidine/pharmacology , Ticlopidine/pharmacokinetics , Adenosine Diphosphate/administration & dosageABSTRACT
A hypothesis is presented that an abnormality of nucleotide synthesis or metabolism might be a primary functional defect underlying Duchenne muscular dystrophy. One aim of this hypothesis is to demonstrate that it is possible to explain a variety of observations in dystrophy, neuromuscular and vascular, on a single hypothesis.